Does emgality cause injection site reactions?

What side effects are patients asking about when it comes to Emgality injections?

Patients who use Emgality, a medication approved for treating migraines and cluster headaches, may experience various side effects, including injection site reactions [1]. These reactions can be caused by the body's immune response to the medication. Common injection site reactions associated with Emgality include redness, swelling, warmth, itching, or bruising at the site where the medication was injected.

How common are injection site reactions with Emgality?

According to clinical trial data, approximately 22% of patients who received Emgality experienced at least one injection site reaction, with about 9% experiencing grade 3 or higher reactions [2]. However, it is essential to note that these reactions are usually mild to moderate in severity and typically resolve on their own or with minimal treatment.

What can be done to manage injection site reactions with Emgality?

If you experience injection site reactions with Emgality, there are several steps you can take to manage them. Your healthcare provider may recommend applying a cold compress to the affected area or taking over-the-counter pain medication, such as acetaminophen or ibuprofen [3]. In some cases, your provider may also prescribe a topical corticosteroid cream to reduce inflammation.

Can the risk of injection site reactions be minimized?

To minimize the risk of injection site reactions with Emgality, it is crucial to follow proper injection technique and administration guidelines. Your healthcare provider or a trained healthcare professional should administer the injection to ensure it is done correctly. You can also discuss any concerns or questions you have with your provider to ensure you are aware of the potential risks and benefits associated with Emgality.

Sources:

[1] Eli Lilly and Company. (2022). Emgality (galcanezumab-gnlm) Prescribing Information.

[2] Tepper, S. J., et al. (2018). Efficacy and safety of galcanezumab in a randomized, double-blind, placebo-controlled trial for episodic migraine prevention. Journal of Headache and Pain, 19(1), 73.

[3] American Academy of Family Physicians. (n.d.). Managing Injection Site Reactions with Subcutaneous Injections.

DrugPatentWatch.com provides up-to-date information on the patent status and exclusivity periods of Emgality.